Protara Therapeutics Total Liab Over Time
| TARA Stock | USD 2.39 0.10 4.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Protara Therapeutics Performance and Protara Therapeutics Correlation. Protara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Protara Therapeutics and related stocks such as Eliem Therapeutics, HCW Biologics, and Scpharmaceuticals Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCWB | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1 M | 2.3 M | 9.4 M | 15.1 M | 15.8 M |
| SCPH | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 76.8 M | 16.1 M | 15 M | 25.9 M | 26.9 M | 22.6 M | 51.8 M | 57.3 M | 38.2 M |
| MIST | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 143.3 M | 8.5 M | 6.9 M | 7.2 M | 8.1 M | 58.5 M | 33.5 M |
| MCRB | 178 K | 178 K | 178 K | 13.2 M | 144.1 M | 11.5 M | 140 M | 128.8 M | 168.5 M | 180.8 M | 168.2 M | 223.4 M | 338 M | 403.5 M | 423.6 M |
| LUMO | 42.4 M | 11.6 M | 11.5 M | 12.2 M | 34.3 M | 22.8 M | 45.3 M | 29.1 M | 15.8 M | 17.9 M | 12.5 M | 11.3 M | 12.7 M | 13.3 M | 21.4 M |
Protara Therapeutics and related stocks such as Eliem Therapeutics, HCW Biologics, and Scpharmaceuticals Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| Protara Therapeutics | TARA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.39
Check out Protara Therapeutics Performance and Protara Therapeutics Correlation. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Protara Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.